Multikinase inhibitor-based immunotherapy doublet for advanced hepatocellular carcinoma: its efficacy still needs to be determined.

Li, Heming; Hao, Xiangjun; Han, Tao

Li, Heming; Hao, Xiangjun; Han, Tao.

Afiliación

Li H; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, China.
Hao X; Department of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang, China.
Han T; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, China.

Hepatobiliary Surg Nutr ; 12(3): 468-471, 2023 Jun 01.

Article en En | MEDLINE | ID: mdl-37351137

Palabras clave

Advanced hepatocellular carcinoma (advanced HCC); clinical trial; hepatitis B virus (HBV); immunotherapy; multikinase inhibitor (MKI)

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Hepatobiliary Surg Nutr Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: China

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google